These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34745459)

  • 1. Manufacturers' views on outcome-based agreements.
    Barjestehvan Waalwijk van Doorn-Khosrovani S; Timmers L; Pisters-van Roy A; Gijzen J; Blijlevens NMA; Bloemendal H
    J Mark Access Health Policy; 2021; 9(1):1993593. PubMed ID: 34745459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial Characteristics of Outcomes-Based Agreements: What Do Canadian Public Payers and Pharmaceutical Manufacturers Prefer?
    Wills A; Mitha A
    Value Health; 2024 Mar; 27(3):340-346. PubMed ID: 38154595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe.
    Avşar TS; Elvidge J; Hawksworth C; Kenny J; Németh B; Callenbach M; Ringkvist J; Dawoud D
    Value Health; 2024 Jul; ():. PubMed ID: 39094693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Building infrastructure for outcomes-based agreements in Canada: can administrative health data be used to support an outcomes-based agreement in oncology?
    Cheung WY; Cameron C; Mitha A; Wills A
    Support Care Cancer; 2022 Dec; 31(1):5. PubMed ID: 36512133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerating patient access to oncology medicines with multiple indications in Europe.
    Lawlor R; Wilsdon T; Darquennes E; Hemelsoet D; Huismans J; Normand R; Roediger A
    J Mark Access Health Policy; 2021; 9(1):1964791. PubMed ID: 34436506
    [No Abstract]   [Full Text] [Related]  

  • 6. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Payer and Pharmaceutical Manufacturer Considerations for Outcomes-Based Agreements in the United States.
    Brown JD; Sheer R; Pasquale M; Sudharshan L; Axelsen K; Subedi P; Wiederkehr D; Brownfield F; Kamal-Bahl S
    Value Health; 2018 Jan; 21(1):33-40. PubMed ID: 29304938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Innovative medicines and market access agreements].
    Toumi M; Zard J; Duvillard R; Jommi C
    Ann Pharm Fr; 2013 Sep; 71(5):302-25. PubMed ID: 24075701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managed Entry Agreements: Policy Analysis From the European Perspective.
    Dabbous M; Chachoua L; Caban A; Toumi M
    Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the status and views of managed entry agreements in Saudi Arabia: mixed-methods approach.
    Al-Omar HA; Alghannam HH; Aljuffali IA
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):837-845. PubMed ID: 32658625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Market access agreements: Definition and features. Could MAA be defined as a solution for immunotherapy funding by French health system?].
    Ceyrac T; Corny J; Raybaut C; Degrassat-Théas A; Paubel P
    Ann Pharm Fr; 2018 Jul; 76(4):265-272. PubMed ID: 29573790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
    Towse A; Garrison LP
    Pharmacoeconomics; 2010; 28(2):93-102. PubMed ID: 20085386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. License Compliance Issues For Biopharmaceuticals: Special Challenges For Negotiations Between Companies And Non-Profit Research Institutions.
    Ponzio TA; Feindt H; Ferguson S
    LES Nouv; 2011 Sep; 46(3):216-225. PubMed ID: 22162900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).].
    Jommi C; Armeni P; Costa F; Alberti C; Bandello F; Bordonaro R; Caprodossi A; Di Maio M; Gaudioso A; Giuliani G; Langella R; Marata AM; Patarnello F; Pinto C; Rasi G; Villa F
    Recenti Prog Med; 2021 Nov; 112(11):749-756. PubMed ID: 34782810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confidentiality agreements: a challenge in market regulation.
    Iunes RF; Uribe MV; Torres JB; Garcia MM; Dias CZ; Alvares-Teodoro J; de Assis Acurcio F; Guerra-Junior AA
    Int J Equity Health; 2019 Jun; 18(1):11. PubMed ID: 31155003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stakeholder views of managed entry agreements: A literature review of national studies.
    Thanimalai S; Choon WY; Lee KK
    Health Policy Open; 2021 Dec; 2():100032. PubMed ID: 37383516
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.